City of Hope Medical Group
Hematology
Dr. Leslie L. Popplewell, MD
|
|
Give Review
Leslie L. Popplewell, MD is an expert in the field of Hematology. She studied medicine at University of Louisville School of Medicine. University of Louisville School of Medicine is ranked 83 in research and 0 in primary care medicine Leslie L. Popplewell, MD is a published MD. She has 44 publications published. The most current publication "Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies." Leslie Popplewell accepts Medicare payments and is listed with Medicare.gov.
Publications
- Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia.
- A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in Acute leukemias: a California Cancer Consortium study.
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin Lymphoma.
- Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for hodgkin Lymphoma.
- Factors associated with high burden in caregivers of older adults with cancer.
- Gene Therapy: Charting a Future Course Summary of a National Institutes of Health Workshop, April 12, 2013.
- Everolimus for patients with mantle cell Lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
- Phase II Study Of The Oral MEK Inhibitor Selumetinib In Advanced Acute Myeloid Leukemia (AML): A University Of Chicago Phase II Consortium Trial.
- Conditional survival and cause-specific mortality after autologous hematopoietic Cell transplantation for hematological malignancies.
- Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, Disease, and treatme...
- Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem Cell transplantation in patients with multiple myeloma.
- Pralatrexate in patients with relapsed or refractory peripheral T-cell Lymphoma: results from the pivotal PROPEL study.
- Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic Leukemia and multiple myeloma.
- Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients ...
- High frequency of pro-B Acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities.
- Therapy-related Acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.
- 21q22 balanced chromosome aberrations in therapy-related hematopoietic Disorders: report from an international workshop.
- Late onset of EBV-driven PTLD/Burkitt lymphoma/Leukemia in a patient 10 years after allogeneic stem cell transplant for AML.
- Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin Lymphoma results in long-term disease control.
- Hematopoietic stem Cell transplantation in the new millennium: report from City of Hope National Medical Center.
- Maintenance thalidomide following single cycle autologous peripheral blood stem Cell transplant in patients with multiple myeloma.
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma Cell growth and survival.
- T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage Leukemia effect.
- A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem Cell transplant...
- Is there an upper age limit for bone marrow transplantation?
- Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's Lymphoma and mantle cell Lymphoma.
- A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid Leukemia.
- Primary anaplastic large-cell Lymphoma associated with breast implants.
- Efficacy of mycophenolate mofetil in the treatment of Chronic graft-versus-host disease.
- Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin Lymphoma.
- Total marrow irradiation: a new ablative regimen as part of tandem autologous stem Cell transplantation for patients with multiple myeloma.
- Allogeneic hematopoietic stem cell transplantation for Acute leukemia, chronic leukemia, and myelodysplasia.
- A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory Acute myelogenous leukemia: impact of cytogenetic characteris...
- Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T Cells in hum...
- Reduced-intensity allogeneic stem Cell transplantation for patients whose prior autologous stem Cell transplantation for hematologic malignancy failed.
- A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
- Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradia...
- Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's Lymphoma.
- Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for Lymphoma.
- Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin Lymphoma.
- Does follicularity in large cell Lymphoma predict outcome after autologous stem cell transplantation?
- High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell Lymphoma (PTCL): analysis of prognostic factors.
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Schools
University of Louisville School of Medicine
Temple University Hospital
City Of Hope
Procedures Preformed
- Bone Marrow Aspiration
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
Temple University Hospital -
University of Louisville School of Medicine
Hospital
-
City of Hope's Helford Clinical Research Hospital
Drug Facts
| NPI NUMBER | 1457310450 | |
| NPPES Provider LastName | POPPLEWELL | |
| NPPES Provider FirstName | LESLIE | |
| NPPES Provider ZIPCode | 910103012 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology | |
| Total Claim Count | 396.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 36.0 | |
| Percent Opioid Claims | 9.09 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457310450 |
| Last Name Of The Provider | POPPLEWELL |
| First Name Of The Provider | LESLIE |
| View All |
Similar Doctors
|
Dr. Arti Hurria, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rytotaro Nakamura, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony Stein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Auyaporn Nademanee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pablo Parker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elleen Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra M. Levine, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Olivia W. Chan, MB |
|
|
Rashmi Batra, MB
This Doctor is OpenDoctor Recommended.
|